RQC Restoration Therapy for Neurodegeneration
Overview
flowchart TD
ideas_payload_rqc_ribosome_qua["RQC Restoration Therapy for Neurodegeneration"]
style ideas_payload_rqc_ribosome_qua fill:#4fc3f7,stroke:#333,color:#000
ideas_payload_rqc_ri_0["Biological Background"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_0
style ideas_payload_rqc_ri_0 fill:#81c784,stroke:#333,color:#000
ideas_payload_rqc_ri_1["The RQC Machinery"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_1
style ideas_payload_rqc_ri_1 fill:#ef5350,stroke:#333,color:#000
ideas_payload_rqc_ri_2["RQC in Neurodegeneration"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_2
style ideas_payload_rqc_ri_2 fill:#ffd54f,stroke:#333,color:#000
ideas_payload_rqc_ri_3["Therapeutic Mechanisms"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_3
style ideas_payload_rqc_ri_3 fill:#ce93d8,stroke:#333,color:#000
ideas_payload_rqc_ri_4["1. RQC Enhancer Small Molecules"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_4
style ideas_payload_rqc_ri_4 fill:#4fc3f7,stroke:#333,color:#000
ideas_payload_rqc_ri_5["2. Rqc2/CAT-Tailing Modulation"]
ideas_payload_rqc_ribosome_qua -->|"includes"| ideas_payload_rqc_ri_5
style ideas_payload_rqc_ri_5 fill:#81c784,stroke:#333,color:#000
...RQC Restoration Therapy for Neurodegeneration
Overview
Mermaid diagram (expand to render)
Ribosome-associated Quality Control (RQC) is a conserved cellular machinery that resolves translational stalls on ribosomes, preventing the production of truncated, toxic protein fragments. Mutations in RQC components—including [Listerin (LTN1)](/entities/ltn1-gene), [Rqc2](/entities/rqc2-protein), and the C-terminal Domain (CTD) of [ZNF598](/entities/znf598-protein)—are directly linked to familial [amyotrophic lateral sclerosis (ALS)](/diseases/als-ftd-spectrum) and [frontotemporal dementia (FTD)](/diseases/frontotemporal-dementia). This therapy proposes enhancing RQC activity to clear stalled translation complexes, reduce toxic protein fragment burden, and restore proteostasis in neurodegenerative conditions.
Biological Background
The RQC Machinery
When a ribosome stalls during translation—due to mRNA damage, codon depletion, or problematic nascent chains—the RQC takes over:
Detection: [ZNF598](/entities/znf598-protein) (aka GIGYF2) and [eIF2A](/entities/eif2a-protein) sense ribosomal collision
Annotation: Rqc2 (NEMF) binds the 60S subunit, adding C-terminal alanine and threonine (CAT) tails via ribosomal protein L10 (RPL10/uL16)
Resolution: Listerin ([LTN1](/entities/ltn1-gene)) functions as an E3 ubiquitin ligase to ubiquitinate the nascent chain
Clearance: The tagged nascent chain is extracted and degraded by the proteasomeRQC in Neurodegeneration
Genetic evidence directly implicates RQC dysfunction in neurodegeneration:
- Listerin (LTN1) mutations: Frameshift mutations near the C-terminus cause autosomal recessive ALS (MND/ALS type 6)
- Rqc2 (NEMF) variants: Associated with ALS-FTD spectrum disorders through impaired CAT-tailing
- ZNF598/GIGYF2: Variants linked to neurodevelopmental delay and Parkinson's disease
- RPL10/uL16: Mutations cause X-linked syndromic intellectual disability with motor phenotypes
RQC failure produces two classes of toxic products: (1) truncated proteins from partially translated mRNAs and (2) CAT-tailed aggregation-prone proteins from Rqc2 activity on the nascent chain.
Therapeutic Mechanisms
1. RQC Enhancer Small Molecules
Target: ZNF598-CTD allosteric modulators, Listerin RING domain activators
Approach:
- Screen for small molecules that increase ZNF598 autophosphorylation or Listerin ubiquitination activity
- Target RQC with compounds that promote ribosomal collision resolution
- Enhance Ltn1-RING activity to increase ubiquitination flux through the pathway
Precedent: Similar screens for E3 ligase activators (e.g., MLN4924 inhibits NEDD8-activating enzyme but activates certain ligases via substrate stabilization)
2. Rqc2/CAT-Tailing Modulation
Target: Rqc2 ([NEMF](/entities/nemf-protein)) interaction interfaces
Approach:
- Stabilize Rqc2-60S interaction to ensure complete CAT-tailing
- Prevent Rqc2 aggregation by small molecules or targeted protein degradation
- Promote productive extraction of CAT-tailed proteins
Mechanism: Enhanced CAT-tailing marks more nascent chains for proteasomal degradation, reducing accumulation of toxic fragments
3. Ribosomal Collision Resolution Enhancement
Target: [HBS1L](/entities/hbs1l-protein)-[ABCE1](/entities/abce1-protein) splitting complex
Approach:
- Increase HBS1L GTPase activity to accelerate ribosome release
- Enhance ABCE1 ATPase activity for efficient ribosome splitting
- Promote Dom34/Hbs1 recruitment to stalled complexes
Benefit: Faster resolution of collisions before RQC machinery is overwhelmed
4. Gene Therapy for RQC Component Overexpression
Target: [Listerin (LTN1)](/entities/ltn1-gene), [Rqc2 (NEMF)](/entities/nemf-protein), [ZNF598](/entities/znf598-protein)
Approach:
- AAV-mediated overexpression of wild-type Listerin in motor neurons and cortical neurons
- Viral delivery of ZNF598 to restore collision-sensing capacity
- CRISPR activation (CRISPRa) of endogenous RQC genes
Priority: Loss-of-function ALS/FTD mutations (particularly recessive LTN1) are the primary indication
Disease Relevance
ALS/FTD (Primary Indication)
- Direct genetic validation: Listerin (LTN1) recessive mutations cause ALS
- Impaired CAT-tailing in NEMF variant carriers
- RQC overload from C9orf72 DPR toxicity creates dependency on RQC machinery
- Score contribution: 10/10 for ALS, 10/10 for FTD
Alzheimer's Disease
- Ribosomal stalling increases in AD brain (tau phosphorylation affects translation)
- RQC dysfunction could contribute to Aβ and tau fragment accumulation
- Amyloid precursor protein ([APP](/genes/app)) contains rare codons that naturally stall ribosomes
- Score contribution: 7/10 for AD
Parkinson's Disease
- α-synuclein ([SNCA](/genes/snca)) mRNA contains secondary structures that slow translation
- Translation stalling increases oxidative stress and protein aggregation
- RQC overload from α-syn overexpression may create vulnerability
- Score contribution: 7/10 for PD
Aging
- RQC efficiency declines with age (proteostasis network decline)
- Accumulation of truncated proteins is a hallmark of aged neurons
- Score contribution: 8/10 for aging
10-Dimension Rubric Scoring
| Dimension | Score (0-10) | Rationale |
|-----------|:---:|---|
| Novelty | 9 | Direct RQC targeting for neurodegeneration is essentially unexplored clinically |
| Mechanistic Rationale | 8 | Strong genetic evidence (LTN1, NEMF, ZNF598); clear biochemical mechanism |
| Root-Cause Coverage | 8 | Addresses proteostasis at the translational level, upstream of aggregation |
| Delivery Feasibility | 5 | Gene therapy (AAV) for motor neurons is established (Spinraza, etc.); small molecules harder to design |
| Safety Plausibility | 7 | RQC is essential but not rate-limiting; partial enhancement likely safe |
| Combinability | 8 | Synergizes with proteasome enhancers, autophagy inducers, and protein synthesis inhibitors |
| Biomarker Availability | 6 | CAT-tailed protein fragments in CSF as candidate biomarker; not yet clinically validated |
| De-risking Path | 7 | Drosophila models available; primary neurons from patient iPSCs accessible |
| Multi-disease Potential | 8 | ALS/FTD primary, AD/PD secondary, aging universal |
| Patient Impact | 7 | ALS/FTD patients have highest unmet need; disease-modifying potential |
Total Score: 73/100
Implementation Roadmap
Phase 1: Target Validation (12 months, $2-3M)
- M1: Validate RQC component expression in post-mortem ALS, AD, PD brain tissue (RNAscope, western blot)
- M2: iPSC-derived motor neurons from LTN1/NEMF mutation carriers: measure CAT-tailed proteins, truncated protein accumulation
- M3: Develop AlphaLISA or SIMOA assay for CAT-tailed protein fragments in human CSF
- M4: DrosophilaALS model (LTN1 knockdown) to confirm truncated protein toxicity and rescue by RQC enhancement
Academic centers: Columbia University (ALS iPSC core), UCSF (neurodegeneration models), University of Edinburgh (RQC biochemistry)
Phase 2: Small Molecule and Gene Therapy Development (24 months, $8-12M)
- M1: High-throughput screen for Listerin RING domain activators (FRET-based ubiquitination assay)
- M2: Develop AAV9-LTN1 construct for CNS delivery (validates against Spinraza's precedent)
- M3: Off-target profiling of hit compounds
- M4: Dose-response studies in primary neurons and human iPSC-derived motor neurons
Companies for partnership: uniQure (AAV-LTN1), Denali Therapeutics (biologics for neurodegeneration), Calico (aging targets)
Phase 3: IND-Enabling Studies (18 months, $10-15M)
- M1: GLP toxicology (AAV9-LTN1: NHP studies)
- M2: GMP manufacturing for lead compound or gene therapy
- M3: IND submission
Estimated total: $20-30M, 54 months to IND
Key Risks and Mitigation
| Risk | Likelihood | Impact | Mitigation |
|------|:---:|:---:|---|
| RQC enhancers cause off-target translation inhibition | Medium | High | Wide therapeutic window expected; titrate carefully |
| AAV9 delivery insufficient for cortical neurons | Medium | High | Use novel capsids (AAV-PHP.eB, AAV-F travasculature) |
| CAT-tailing enhancement produces new toxic species | Low | High | Monitor in Phase 1-2 assays |
| Limited commercial incentive (small patient population) | Medium | Medium | Pursue orphan designation; combination with larger indications |
Actionable Next Steps
Lab Experiments
Validate RQC impairment in ALS-FTD patient iPSC-derived motor neurons (measure CAT-tailed proteins by western blot with anti-alanine antibody)
Test whether Listerin overexpression rescues neurodegeneration phenotypes in patient neurons
Screen for small molecules that increase Listerin ubiquitination activity in vitro
Develop mass spectrometry assay for RQC-generated truncated proteins in human brain tissueClinical Protocol Design
Phase 1/2a trial design: AAV9-LTN1 intrathecal administration in ALS patients with confirmed LTN1/NEMF mutations
Biomarker: measure CAT-tailed protein fragments in CSF before and after treatment
Primary endpoint: survival, ALSFRS-R decline rate, CSF biomarkersCompany Partnership Opportunities
- uniQure (AAV gene therapy for neurodegenerative diseases)
- Denali Therapeutics (precision medicine approach for neurodegenerative diseases)
- Roche/Genentech (neuroscience pipeline, ALS/FTD focus)
Grant Opportunities
- ALS Association Therapeutic Idea Award
- NINDS R01: Gene therapy for rare forms of ALS
- The Wellcome Trust: Translation of RQC modulators
Cross-Linking
- [Listerin (LTN1) gene](/entities/ltn1-gene) — primary target gene
- [Rqc2 (NEMF) protein](/entities/nemf-protein) — RQC component
- [ZNF598 protein](/entities/znf598-protein) — collision sensor
- [Proteostasis pathways](/mechanisms/proteostasis-network) — broader context
- [ALS-FTD spectrum disease](/diseases/als-ftd-spectrum) — primary disease indication
- [Protein synthesis and translation quality control](/mechanisms/protein-synthesis-quality-control) — mechanistic context